Skin Cleanser for Eczema

Recruiting in Palo Alto (17 mi)

Age: Any Age

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 4

Waitlist Available

Sponsor: Boston Children's Hospital

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?Our hypothesis is that S. aureus skin decolonization in atopic dermatitis reduces disease severity and favorably alters the function and gene expression of epidermal and immune skin cells that contribute to disease severity.

Eligibility Criteria

This trial is for males and females aged 6 years or older who have been diagnosed with atopic dermatitis, a type of eczema. Participants must have a SCORAD (a measure of eczema severity) greater than 40 to join.

Inclusion Criteria

I am 6 years old or older.

SCORAD > 40

Meet atopic dermatitis Standard Diagnostic Criteria

Exclusion Criteria

Enrollment in another clinical trial

I do not have severe ongoing illnesses like heart or kidney disease.

Febrile illness at time of visits

+12 more

Participant Groups

The study is testing whether using Skin Cleanser Combination No.1 can reduce the severity of atopic dermatitis by removing S. aureus bacteria from the skin and improving skin cell function.

1Treatment groups

Experimental Treatment

Group I: Skin Cleansing RegimenExperimental Treatment1 Intervention

1. Mupirocin 2% nasal ointment to the anterior nares to be applied twice daily 2. Chlorhexidine 4% topical soap (Hibiclens) to be used every other day in the shower or bath from the neck down and then completely rinsed. 3. Sulfamethoxazole/trimethoprim (Bactrim): one double strength (DS) tablet (800 mg/160 mg) twice per day for adolescents and adults